PL377112A1 - Sposoby wytwarzania związków pirolotriazynowych użytecznych jako inhibitory kinazy - Google Patents

Sposoby wytwarzania związków pirolotriazynowych użytecznych jako inhibitory kinazy

Info

Publication number: PL377112A1
Authority: PL; Poland
Prior art keywords: methods; sub; preparation; kinase inhibitors; compounds useful
Prior art date: 2002-11-06

Application number

PL377112A

Other languages

English (en)

Inventor

Jollie Duaine Godfrey Jr.

John Hynes Jr.

Alaric J. Dyckman

Katerina Leftheris

Zhongping Shi

Stephen T. Wrobleski

Wendel William Doubleday

John A. Grosso

Original Assignee

Bristol-Myers Squibb Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-11-06

Filing date

2003-11-03

Publication date

2006-01-23

2003-11-03 Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company

2006-01-23 Publication of PL377112A1 publication Critical patent/PL377112A1/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/50—Nitrogen atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Physical Education & Sports Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pulmonology (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Pyrrole Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

PL377112A 2002-11-06 2003-11-03 Sposoby wytwarzania związków pirolotriazynowych użytecznych jako inhibitory kinazy PL377112A1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US10/289,010 US6867300B2 (en)	2000-11-17	2002-11-06	Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors

Publications (1)

Publication Number	Publication Date
PL377112A1 true PL377112A1 (pl)	2006-01-23

Family

ID=32312096

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL377112A PL377112A1 (pl)	2002-11-06	2003-11-03	Sposoby wytwarzania związków pirolotriazynowych użytecznych jako inhibitory kinazy

Country Status (16)

Country	Link
US (2)	US6867300B2 (pl)
EP (1)	EP1562949B1 (pl)
JP (1)	JP4662775B2 (pl)
KR (1)	KR20050084961A (pl)
CN (1)	CN100360532C (pl)
AT (1)	ATE453645T1 (pl)
AU (1)	AU2003287514A1 (pl)
BR (1)	BR0316056A (pl)
CA (1)	CA2505365A1 (pl)
CO (1)	CO5560547A2 (pl)
DE (1)	DE60330800D1 (pl)
ES (1)	ES2337571T3 (pl)
MX (1)	MXPA05004748A (pl)
PL (1)	PL377112A1 (pl)
TW (1)	TWI290555B (pl)
WO (1)	WO2004043912A2 (pl)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6982265B1 (en) *	1999-05-21	2006-01-03	Bristol Myers Squibb Company	Pyrrolotriazine inhibitors of kinases
US6867300B2 (en) *	2000-11-17	2005-03-15	Bristol-Myers Squibb Company	Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US6670357B2 (en) *	2000-11-17	2003-12-30	Bristol-Myers Squibb Company	Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
TW200300350A (en) *	2001-11-14	2003-06-01	Bristol Myers Squibb Co	C-5 modified indazolylpyrrolotriazines
PT1497019E (pt) *	2002-04-23	2015-09-10	Bristol Myers Squibb Co	Compostos de pirrolotriazina anilina úteis como inibidores de quinase
US7388009B2 (en)	2002-04-23	2008-06-17	Bristol-Myers Squibb Company	Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors
ES2318122T3 (es)	2002-04-23	2009-05-01	Bristol-Myers Squibb Company	Compuestos de aril cetona pirrolo-triazina utiles como inhibidores de quinasa.
TW200401638A (en) *	2002-06-20	2004-02-01	Bristol Myers Squibb Co	Heterocyclic inhibitors of kinases
TWI329112B (en) *	2002-07-19	2010-08-21	Bristol Myers Squibb Co	Novel inhibitors of kinases
TW200420565A (en)	2002-12-13	2004-10-16	Bristol Myers Squibb Co	C-6 modified indazolylpyrrolotriazines
JP2006516653A (ja)	2003-02-05	2006-07-06	ブリストル−マイヤーズ　スクイブ　カンパニー	キナーゼ阻害剤ピロロトリアジンの製造方法
US20060014741A1 (en) *	2003-12-12	2006-01-19	Dimarco John D	Synthetic process, and crystalline forms of a pyrrolotriazine compound
US7102001B2 (en)	2003-12-12	2006-09-05	Bristol-Myers Squibb Company	Process for preparing pyrrolotriazine
MY145634A (en) *	2003-12-29	2012-03-15	Bristol Myers Squibb Co	Pyrrolotriazine compounds as kinase inhibitors
US7064203B2 (en)	2003-12-29	2006-06-20	Bristol Myers Squibb Company	Di-substituted pyrrolotriazine compounds
US7829720B2 (en)	2004-05-04	2010-11-09	Bristol-Myers Squibb Company	Process for preparing atazanavir bisulfate and novel forms
TWI354569B (en)	2004-05-28	2011-12-21	Bristol Myers Squibb Co	Coated tablet formulation and method
US7102002B2 (en) *	2004-06-16	2006-09-05	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US7439246B2 (en) *	2004-06-28	2008-10-21	Bristol-Myers Squibb Company	Fused heterocyclic kinase inhibitors
US7173031B2 (en) *	2004-06-28	2007-02-06	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US7432373B2 (en) *	2004-06-28	2008-10-07	Bristol-Meyers Squibb Company	Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7253167B2 (en) *	2004-06-30	2007-08-07	Bristol-Myers Squibb Company	Tricyclic-heteroaryl compounds useful as kinase inhibitors
TW200600513A (en) *	2004-06-30	2006-01-01	Bristol Myers Squibb Co	A method for preparing pyrrolotriazine compounds
US7102003B2 (en) *	2004-07-01	2006-09-05	Bristol-Myers Squibb Company	Pyrrolotriazine compounds
US7504521B2 (en) *	2004-08-05	2009-03-17	Bristol-Myers Squibb Co.	Methods for the preparation of pyrrolotriazine compounds
US7148348B2 (en)	2004-08-12	2006-12-12	Bristol-Myers Squibb Company	Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
EP1812439B2 (en) †	2004-10-15	2017-12-06	Takeda Pharmaceutical Company Limited	Kinase inhibitors
US7151176B2 (en) *	2004-10-21	2006-12-19	Bristol-Myers Squibb Company	Pyrrolotriazine compounds
US7514435B2 (en) *	2005-11-18	2009-04-07	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US7348325B2 (en) *	2005-11-30	2008-03-25	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
CA2631741C (en)	2005-12-02	2014-01-28	Bayer Healthcare Llc	Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
PE20070855A1 (es)	2005-12-02	2007-10-14	Bayer Pharmaceuticals Corp	Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
US8063208B2 (en)	2006-02-16	2011-11-22	Bristol-Myers Squibb Company	Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
EP2235001B1 (en)	2008-01-23	2014-12-24	Bristol-Myers Squibb Company	Process for preparing pyridinone compounds
AR074830A1 (es)	2008-12-19	2011-02-16	Cephalon Inc	Pirrolotriazinas como inhibidores de alk y jak2
WO2012031057A1 (en)	2010-09-01	2012-03-08	Bristol-Myers Squibb Company	Bms- 582949 for the treatment of resistant rheumatic disease
CN102153558B (zh) *	2011-02-23	2012-11-21	扬州永济医药新技术有限公司	多靶点抗肿瘤抑制剂2-氨吡咯-三嗪的衍生物及其合成方法
US9724352B2 (en)	2012-05-31	2017-08-08	Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences	Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof
CN103450204B (zh)	2012-05-31	2016-08-17	中国科学院上海药物研究所	吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
CN104003990B (zh) *	2013-02-21	2017-09-15	江苏先声药业有限公司	杂环胺类Hedgehog信号通路抑制剂
US9050345B2 (en)	2013-03-11	2015-06-09	Bristol-Myers Squibb Company	Pyrrolotriazines as potassium ion channel inhibitors
CN104788460B (zh) *	2015-03-27	2016-11-09	陕西师范大学	4-芳氨基吡咯并[2,1-f][1,2,4]三嗪衍生物的制备方法
WO2019168874A1 (en)	2018-02-27	2019-09-06	The Research Foundation For The State University Of New York	Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
CN108516977A (zh) *	2018-07-10	2018-09-11	刘凤娟	一种用于治疗恶性肿瘤的map激酶抑制剂的合成方法
CN111234067B (zh) *	2018-11-29	2021-08-03	中国石油化工股份有限公司	用于烯烃聚合的固体催化剂组分和催化剂及其应用
CN113372263B (zh) *	2021-05-21	2022-04-19	温州医科大学	一种2-氯-3-胺基萘醌化合物的制备方法
CN113292503B (zh) *	2021-05-22	2022-05-13	台州市第一人民医院	一种2-溴-3-胺基萘醌化合物的制备方法
CN116789674B (zh) *	2022-08-24	2024-05-24	杭州高光制药有限公司	Nlrp3炎性小体抑制剂

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4908056A (en) *	1986-04-25	1990-03-13	E. I. Du Pont De Nemours And Company	Heterocyclic acyl sulfonamides
EP0682027B1 (de) *	1994-05-03	1997-10-15	Novartis AG	Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
CA2163399A1 (en)	1994-11-24	1996-05-25	Katsuhiro Kawano	Triazine derivative, chymase activity inhibitor and nitric oxide production inhibitor
IL118544A (en)	1995-06-07	2001-08-08	Smithkline Beecham Corp	History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
EP0778277B1 (en)	1995-12-08	2003-06-25	Pfizer Inc.	Substituted heterocyclic derivatives as CRF antagonists
ES2205167T3 (es)	1996-01-11	2004-05-01	Smithkline Beecham Corporation	Nuevos compuestos de imidazol sustituidos.
GB9604361D0 (en)	1996-02-29	1996-05-01	Pharmacia Spa	4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
PL332040A1 (en)	1996-08-28	1999-08-16	Pfizer	Substitution 6,5-heterobicyclic derivatives
US20010007867A1 (en) *	1999-12-13	2001-07-12	Yuhpyng L. Chen	Substituted 6,5-hetero-bicyclic derivatives
US5945418A (en)	1996-12-18	1999-08-31	Vertex Pharmaceuticals Incorporated	Inhibitors of p38
US6147080A (en)	1996-12-18	2000-11-14	Vertex Pharmaceuticals Incorporated	Inhibitors of p38
KR20010012808A (ko)	1997-05-22	2001-02-26	윌리암스 로저 에이	ｐ38 키나아제로서 4-아릴-3(5)-헤테로아릴 치환 피라졸
US6087496A (en)	1998-05-22	2000-07-11	G. D. Searle & Co.	Substituted pyrazoles suitable as p38 kinase inhibitors
AU8381098A (en)	1997-07-02	1999-01-25	Smithkline Beecham Corporation	Novel cycloalkyl substituted imidazoles
WO1999024033A1 (en)	1997-11-12	1999-05-20	Shionogi & Co., Ltd.	Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds
US6130235A (en)	1998-05-22	2000-10-10	Scios Inc.	Compounds and methods to treat cardiac failure and other disorders
US6410540B1 (en)	1998-08-28	2002-06-25	Scios, Inc.	Inhibitors of p38-αkinase
US6184226B1 (en)	1998-08-28	2001-02-06	Scios Inc.	Quinazoline derivatives as inhibitors of P-38 α
ATE232205T1 (de)	1998-10-01	2003-02-15	Astrazeneca Ab	Chinolin- und chinazolin derivate und ihre verwendung als inhibitoren von krankheiten, bei denen cytokine beteiligt wird
GB9906566D0 (en)	1999-03-23	1999-05-19	Zeneca Ltd	Chemical compounds
DE60042620D1 (de)	1999-05-21	2009-09-03	Bristol Myers Squibb Co	Pyrrolotriazine als Kinase Hemmer.
AU6473600A (en) *	1999-08-23	2001-03-19	Shionogi & Co., Ltd.	Pyrrolotriazine derivatives having spla2-inhibitory activities
GB9924092D0 (en)	1999-10-13	1999-12-15	Zeneca Ltd	Pyrimidine derivatives
IL139197A0 (en)	1999-10-29	2001-11-25	Pfizer Prod Inc	Use of corticotropin releasing factor antagonists and related compositions
WO2001034605A1 (en)	1999-11-10	2001-05-17	Ortho-Mcneil Pharmaceutical, Inc.	SUBSTITUTED 2-ARYL-3-(HETEROARYL)-IMIDAZO[1,2-a]PYRIMIDINES, AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS
US6906067B2 (en) *	1999-12-28	2005-06-14	Bristol-Myers Squibb Company	N-heterocyclic inhibitors of TNF-α expression
US20020065270A1 (en)	1999-12-28	2002-05-30	Moriarty Kevin Joseph	N-heterocyclic inhibitors of TNF-alpha expression
DE60043397D1 (de)	1999-12-28	2010-01-07	Pharmacopeia Inc	Cytokine, insbesondere tnf-alpha, hemmer
EP1149583A3 (en) *	2000-04-13	2001-11-14	Pfizer Products Inc.	Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
US6518269B1 (en) *	2000-07-28	2003-02-11	University Of Arizona Foundation	Cancer treatment
BR0115446A (pt)	2000-11-17	2005-08-09	Bristol Myers Squibb Co	Processos para tratamento de condições associadas a quinase p38 e compostos pirrolotriazina úteis como inibidores de quinase
US6670357B2 (en) *	2000-11-17	2003-12-30	Bristol-Myers Squibb Company	Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US6867300B2 (en)	2000-11-17	2005-03-15	Bristol-Myers Squibb Company	Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US20030139435A1 (en) *	2001-06-26	2003-07-24	Gulzar Ahmed	N-heterocyclic inhibitors of TNF-alpha expression
TW200300350A (en) *	2001-11-14	2003-06-01	Bristol Myers Squibb Co	C-5 modified indazolylpyrrolotriazines
US7388009B2 (en)	2002-04-23	2008-06-17	Bristol-Myers Squibb Company	Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors
ES2318122T3 (es)	2002-04-23	2009-05-01	Bristol-Myers Squibb Company	Compuestos de aril cetona pirrolo-triazina utiles como inhibidores de quinasa.
PT1497019E (pt) *	2002-04-23	2015-09-10	Bristol Myers Squibb Co	Compostos de pirrolotriazina anilina úteis como inibidores de quinase
TW200407143A (en) *	2002-05-21	2004-05-16	Bristol Myers Squibb Co	Pyrrolotriazinone compounds and their use to treat diseases
US6933386B2 (en) *	2002-07-19	2005-08-23	Bristol Myers Squibb Company	Process for preparing certain pyrrolotriazine compounds
TWI329112B (en) *	2002-07-19	2010-08-21	Bristol Myers Squibb Co	Novel inhibitors of kinases
WO2004013145A1 (en)	2002-08-02	2004-02-12	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
TW200420565A (en) *	2002-12-13	2004-10-16	Bristol Myers Squibb Co	C-6 modified indazolylpyrrolotriazines
JP2006516653A (ja)	2003-02-05	2006-07-06	ブリストル−マイヤーズ　スクイブ　カンパニー	キナーゼ阻害剤ピロロトリアジンの製造方法
US7419978B2 (en) *	2003-10-22	2008-09-02	Bristol-Myers Squibb Company	Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
US7102001B2 (en) *	2003-12-12	2006-09-05	Bristol-Myers Squibb Company	Process for preparing pyrrolotriazine
US7064203B2 (en) *	2003-12-29	2006-06-20	Bristol Myers Squibb Company	Di-substituted pyrrolotriazine compounds
MY145634A (en) *	2003-12-29	2012-03-15	Bristol Myers Squibb Co	Pyrrolotriazine compounds as kinase inhibitors

2002
- 2002-11-06 US US10/289,010 patent/US6867300B2/en not_active Expired - Fee Related
2003
- 2003-11-03 ES ES03781756T patent/ES2337571T3/es not_active Expired - Lifetime
- 2003-11-03 JP JP2004551735A patent/JP4662775B2/ja not_active Expired - Fee Related
- 2003-11-03 CA CA002505365A patent/CA2505365A1/en not_active Abandoned
- 2003-11-03 AU AU2003287514A patent/AU2003287514A1/en not_active Abandoned
- 2003-11-03 BR BR0316056-4A patent/BR0316056A/pt not_active IP Right Cessation
- 2003-11-03 WO PCT/US2003/035220 patent/WO2004043912A2/en active Application Filing
- 2003-11-03 DE DE60330800T patent/DE60330800D1/de not_active Expired - Lifetime
- 2003-11-03 CN CNB2003801082297A patent/CN100360532C/zh not_active Expired - Fee Related
- 2003-11-03 EP EP03781756A patent/EP1562949B1/en not_active Expired - Lifetime
- 2003-11-03 MX MXPA05004748A patent/MXPA05004748A/es active IP Right Grant
- 2003-11-03 PL PL377112A patent/PL377112A1/pl not_active Application Discontinuation
- 2003-11-03 KR KR1020057008063A patent/KR20050084961A/ko not_active Application Discontinuation
- 2003-11-03 AT AT03781756T patent/ATE453645T1/de not_active IP Right Cessation
- 2003-11-04 TW TW092130839A patent/TWI290555B/zh not_active IP Right Cessation
2004
- 2004-12-22 US US11/019,788 patent/US7211666B2/en not_active Expired - Fee Related
2005
- 2005-05-05 CO CO05043491A patent/CO5560547A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
DE60330800D1 (de)	2010-02-11
JP2006514622A (ja)	2006-05-11
US20050107462A1 (en)	2005-05-19
TWI290555B (en)	2007-12-01
US7211666B2 (en)	2007-05-01
TW200413382A (en)	2004-08-01
WO2004043912A3 (en)	2004-07-01
MXPA05004748A (es)	2005-08-03
US6867300B2 (en)	2005-03-15
ATE453645T1 (de)	2010-01-15
US20030186982A1 (en)	2003-10-02
CA2505365A1 (en)	2004-05-27
CN100360532C (zh)	2008-01-09
AU2003287514A1 (en)	2004-06-03
WO2004043912A2 (en)	2004-05-27
EP1562949B1 (en)	2009-12-30
EP1562949A2 (en)	2005-08-17
KR20050084961A (ko)	2005-08-29
JP4662775B2 (ja)	2011-03-30
CO5560547A2 (es)	2005-09-30
BR0316056A (pt)	2005-09-27
CN1735615A (zh)	2006-02-15
ES2337571T3 (es)	2010-04-27
EP1562949A4 (en)	2007-09-12

Legal Events

Date	Code	Title	Description
2012-05-31	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
PL377112A1 (pl)	2006-01-23	Sposoby wytwarzania związków pirolotriazynowych użytecznych jako inhibitory kinazy
UA90763C2 (ru)	2010-05-25	Производные пиразола, способ их получения, фармацевтический состав на их основе и их применение
WO2005037825A3 (en)	2006-03-30	Protein kinase inhibitors
NO20075142L (no)	2007-11-05	krystallformer av asenapinmaleat
EA200401378A1 (ru)	2005-06-30	N-замещенные трициклические 3-аминопиразолы в качестве ингибиторов pdgf рецептора
MXPA02012795A (es)	2004-07-30	Carvedilol.
NO20081941L (no)	2008-04-23	Pyrazol [1,5-alfa]pyrimidinylderivater nyttige som kortikotropin-frigivende faktor (CRF) reseptorantagonister
IL150883A0 (en)	2003-02-12	Pyrimidine compounds
UA93043C2 (ru)	2011-01-10	ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ ДЛЯ ПОЛУЧЕНИЯ ТРАНС-5-ХЛОР-2-МЕТИЛ-2,3,3А,12В-ТЕТРАГИДРО-1Н-ДИБЕНЗ[2,3:6,7]ОКСЕПИНО[4,5-с]ПИРОЛА
TW200500339A (en)	2005-01-01	Pyrrolidine derivatives, and process for the preparation
EP1451163A4 (en)	2005-01-26	3-AMIDO-1,2-BENZOXOXAZOLE DERIVATIVES, METHOD OF MANUFACTURE AND ITS USE
IL174678A0 (en)	2006-08-20	Arylindenophyridines and arylindenophyrimidines and their use as adenosine a2a receptor antagonist
ATE352543T1 (de)	2007-02-15	Ein dioxino(2,3-g)chinolin-9-carbonsäure derivat als nk3 rezeptor antagonist
MY138826A (en)	2009-07-31	2,7-substituted indoles
RS20060239A (en)	2008-06-05	Arylalkylcarbamate derivatives, preparation method thereof and use of same in therapeutics
NO20070550L (no)	2007-03-26	Fremgangsmate for fremstilling av pyrrolotriazinforbindelser
WO2006029210A3 (en)	2006-05-04	Acyclic 1,3-diamines and uses therefor
HK1080282A1 (en)	2006-04-21	Improved formulations containing substituted imidazole derivatives
AU5936901A (en)	2002-02-13	Process for preparing azacycloalkanoylaminothiazoles
ITMI20020933A1 (it)	2003-11-03	Procedimento per la sintesi di clopidogrel
WO2003076426A3 (en)	2004-07-22	Pyridinyloxy derivatives as 5-ht receptor ligands
CA2432138A1 (en)	2002-06-27	New process for the preparation of eletriptan
SE0301371D0 (sv)	2003-05-09	New Compounds
NO20063299L (no)	2006-07-17	Syntese av en polymorf av 4-amino-5-klor-2-metoksy-N-(1-azabisyklo[3.3.1]non-4-yl)benzamidhydrokloridhydrat
MX2007004400A (es)	2007-06-19	Procedimiento para la preparacion de n-(3,5-dicloropirid-a-il)-4- ifluorometoxi-8-metanosulfonamido-dibenzo [b,d] difuran-1-carboxamida.